A humanized monoclonal antibody targeting Staphylococcus aureus

• Published in: Vaccine Vol. 22; pp. S39 - S43
• Main Author: Patti, Joseph M.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 06.12.2004
• Subjects: Adhesin; Adhesins, Bacterial - immunology; Adhesins, Bacterial - metabolism; Animals; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Cross Infection - prevention & control; Humans; Mice; Monoclonal antibodies; MSCRAMM; Rabbits; Staphylococcal Infections - prevention & control; Staphylococcus aureus; Staphylococcus aureus - immunology; Monoclonal antibodies; Adhesin; MSCRAMM; Staphylococcus aureus
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2004.08.015

This current presentation describes the in vitro and in vivo characterization of Aurexis ® (tefibazumab), a humanized monoclonal antibody that exhibits a high affinity and specificity and for the Staphylococcus aureus MSCRAMM ® (Microbial Surface Components Recognizing Adhesive Matrix Molecules) protein ClfA. Aurexis ® inhibited ClfA binding to human fibrinogen, and enhanced the opsonophagocytic uptake of ClfA-coated beads. Preclinical in vivo testing revealed that a single administration of Aurexis ® significantly protected against an IV challenge with a methicillin resistant S. aureus (MRSA) strain in murine septicemia and rabbit infective endocarditis (IE) models. Safety and pharmacokinetic data from a 19-patient phase I study support continued evaluation of Aurexis ® in phase II studies.